Core Viewpoint - The company, Yingke Recycling Resources Co., Ltd., is participating in an investment in Warburg Pincus Global Growth 15, L.P. as a limited partner, contributing $30 million, which represents approximately 0.18% of the fund's target size of $1.7 billion [2][8]. Group 1: Investment Overview - The investment is aimed at optimizing the company's investment structure and enhancing its global strategic layout [4][16]. - The investment will be made by the company's wholly-owned subsidiary, Yingke Environmental International (Hong Kong) [2][5]. - The investment is classified as a related party transaction due to the common control by the same actual controller with Yingke Medical Technology Co., Ltd. [2][6]. Group 2: Board Approval Process - The investment has been approved by various committees within the company, including the Strategic and ESG Committee, Audit Committee, and Independent Directors [3][27][28]. - The board meeting where the investment was approved had independent directors recuse themselves from voting, ensuring compliance with regulations [29]. Group 3: Fund Details - The fund, Warburg Pincus Global Growth 15, L.P., aims to invest in sectors such as energy transition, sustainable development, commercial services, industrial, technology, consumer, and healthcare [8][19]. - The fund has a lifespan of 12 years, with the possibility of a 2-year extension [8][12]. - The fund's management fee structure is set at 1.3% for the first eight years, decreasing to 1% thereafter [13]. Group 4: Financial Impact and Rationale - The investment is expected to enhance the company's profitability and align with its long-term strategic goals [16][21]. - The company has maintained positive cash flow over the past three years, indicating financial stability to support this investment [20]. - The investment is structured to minimize risk through professional management and diversified investment strategies [20][21].

Core Viewpoint - Yingke Medical (300677.SZ) plans to invest in Warburg Pincus Global Growth 15, L.P. through its wholly-owned subsidiary, Yingke Medical International (Hong Kong) Limited, committing $70 million as a limited partner in a fund targeting a total raise of $17 billion [1] Group 1 - Yingke Medical International will participate in the investment using its own funds [1] - The partnership aims to invest in sectors including healthcare, energy transition, business services, industrial, technology, consumer, and sustainable development [1] - The fund will focus on growth capital transactions, early-stage growth platforms, acquisitions, capital restructuring, and other special situations [1]

Core Viewpoint - In a recent announcement, Yingke Medical (300677) disclosed its plan to invest in Warburg Pincus Global Growth 15, L.P. through its wholly-owned subsidiary, Yingke Medical International, committing $70 million as a limited partner in a fund targeting a total fundraising goal of $17 billion [1] Group 1: Investment Details - Yingke Medical International will invest $70 million in Warburg Pincus Global Growth 15, L.P. as a limited partner [1] - The fund aims to raise a total of $17 billion [1] Group 2: Fund Focus Areas - The fund will focus on growth capital transactions in sectors such as healthcare, energy transition, business services, industrials, technology, consumer goods, and sustainable development [1]